iDose drives record sales, but coverage risks emerge
- Q2 2026 net sales rose 50% year over year to $185.6 million, driven by a strong iDose TR launch.
- U.S. Glaucoma sales hit $118.5 million in Q2 2026, up 64% year over year, with $74 million from iDose TR.
- Corneal Health grew 48% year over year to $30.4 million as Epioxa contributed $11 million.
- The company raised full-year 2026 net sales guidance to a range of $680 million to $700 million.
- Five of seven Medicare contractors proposed coverage limits for iDose TR, creating a new reimbursement risk.
A high-growth launch facing new hurdles
Glaukos relies on the fast-growing iDose TR implant. The product is a tiny device that slowly releases glaucoma medicine inside the eye. In Q2 2026, it produced $74 million of sales and helped push total net sales up 50% year over year to $185.6 million.
The bull case centers on exceptional commercial execution. iDose TR is rapidly establishing itself as the standard of care. Epioxa, the newer corneal cross-linking product, also started well and contributed $11 million in the second quarter. The company expects the Epioxa transition to finish by the end of Q3 2026, supported by a permanent J-code that became active in July.
The bear case is about a new reimbursement threat and ongoing profit pressure. Five of the seven Medicare Administrative Contractors recently proposed local coverage determinations that could restrict access to iDose TR. If finalized, these rules could slow the main growth engine of the business.
Glaukos remains unprofitable as it invests heavily in its commercial infrastructure. It needs sales to continue scaling quickly to reach cash flow breakeven.
Small eye markets, specialized tools
Glaukos makes money by selling products used by eye doctors and surgeons. Its main markets are glaucoma, corneal disorders, and future retinal disease programs. These are niche markets, but the products can be high value because they treat serious eye disease.
The glaucoma business includes tiny devices used in less invasive glaucoma surgery, plus iDose TR and surgical adjuncts like Mitosol. Mitosol is an FDA-approved product used to reduce scarring in glaucoma filtration surgery.
The corneal business includes Photrexa and Epioxa. Epioxa is important because it is an epi-on corneal cross-linking product, meaning the surface layer of the cornea does not need to be removed in the same way as older procedures.
The model breaks if doctors do not adopt the new products, if payers do not cover them well, or if reimbursement codes fail to make the work profitable for clinics. A permanent J-code for Epioxa became effective on July 1, 2026, but Medicare coverage limits could threaten the glaucoma side.
What doctors actually use
iDose TR
This long-duration travoprost implant is the center of the current growth story. In Q2 2026, it produced $74 million of sales, and FDA labeling allows unlimited re-administration in eligible patients.
iStent family
These tiny devices built the glaucoma franchise. The legacy stent business faces headwinds in the United States, but it still gives Glaukos doctor relationships and a base to sell from.
Epioxa
Epioxa treats keratoconus with an epi-on cross-linking approach. It generated $11 million in Q2 2026, and its permanent J-code became active on July 1, 2026.
Photrexa
Photrexa is the older corneal cross-linking product. It is still producing some sales, but Glaukos is transitioning doctors to Epioxa by the end of Q3 2026.
Mitosol
Mitosol came from the Mobius Therapeutics deal. It is an FDA-approved mitomycin-C formulation used to help prevent scarring in glaucoma filtration surgery.
iDose TREX, iDose TRIO, and screening tools
These are pipeline programs that could extend growth beyond the first iDose TR wave. They still carry normal clinical, regulatory, and launch risk.
Glaucoma is the engine
The mix below uses Q2 2026 net sales of $185.6 million. Corneal Health was $30.4 million, and Glaucoma was $155.1 million across U.S. and international markets.
What could go wrong
Medicare coverage limits
High impact · Medium oddsFive of seven Medicare Administrative Contractors proposed local coverage determinations for iDose TR in Q2 2026. If finalized restrictively, these rules could cut off patient access and disrupt the primary growth engine.
iDose TR growth slows
High impact · Low oddsiDose TR generated $74 million in Q2 2026 sales, and U.S. Glaucoma grew 64% year over year. If new patient starts or doctor adoption slow for any reason, the company could miss the growth level investors expect.
Epioxa access disappoints
High impact · Medium oddsThe permanent J-code for Epioxa helps doctors bill for the product, but it does not guarantee broad payer coverage. If clinics face payment delays, the Corneal Health launch could flatten after the early start.
Costs outrun sales
High impact · Medium oddsGlaukos is still unprofitable. The company spends heavily to fund its launches and pipeline work. The business needs sales growth to scale faster than spending to reach cash flow breakeven.
Legacy stents keep shrinking
Medium impact · Medium oddsThe older non-iDose glaucoma business is a drag. The 2025 10-K described a single digit decline in non-iDose net sales. If that decline deepens, iDose TR must do even more work to carry the total company growth.
Valuation leaves little room
Medium impact · Medium oddsThe market already gives Glaukos credit for a strong launch path. That makes the stock sensitive to even small signs of slower iDose TR growth, weaker Epioxa uptake, or delayed profitability.
In one breath
What does Glaukos sell?
Glaukos sells eye care devices, drug implants, and related medicines. Its main areas are glaucoma and corneal disease.
Why is iDose TR important for Glaukos?
iDose TR is the main growth driver right now. It generated $74 million in Q2 2026 sales and helped U.S. Glaucoma sales grow 64% year over year.
What is the biggest risk for GKOS stock?
New proposed rules from Medicare contractors could limit patient access to iDose TR. Additionally, the company is still unprofitable and is spending heavily to support its new launches.
What is the Epioxa J-code and why does it matter?
A J-code is a billing code that helps doctors and clinics get paid for a drug or procedure. Epioxa's permanent J-code became effective on July 1, 2026, which should make the launch easier to scale.
